Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash from Investing Activities (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Cash from Investing Activities data on record, last reported at -$2.1 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 57.13% year-over-year to -$2.1 million; the TTM value through Dec 2025 reached -$31.4 million, down 29.15%, while the annual FY2025 figure was -$31.4 million, 29.15% down from the prior year.
  • Cash from Investing Activities reached -$2.1 million in Q4 2025 per MRVI's latest filing, up from -$2.9 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $118.6 million in Q3 2021 and bottomed at -$241.6 million in Q1 2022.
  • Average Cash from Investing Activities over 5 years is -$17.0 million, with a median of -$5.8 million recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: surged 1275.58% in 2021, then crashed 7867.81% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$5.7 million in 2021, then tumbled by 227.44% to -$18.5 million in 2022, then surged by 30.33% to -$12.9 million in 2023, then surged by 61.78% to -$4.9 million in 2024, then soared by 57.13% to -$2.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$2.1 million in Q4 2025, -$2.9 million in Q3 2025, and -$3.2 million in Q2 2025.